Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
FSGS is an immunologic disorder wherein circulating immune proteins cause damage to the kidneys and progressive injury and scarring. Corticosteroid therapy is occasionally, but not nearly universally, successful in reducing proteinuria, and when patients respond, they have a favorable prognosis. The investigators believe that ACTH therapy (H.P. Acthar Gel) can provide a more rapid, well tolerated reduction in glomerular injury.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : H.P. Acthar Gel
Phase: Phase 4
Ages Eligible For Study:
- 1. Biopsy proven FSGS - 2. Ability to consent and complete study evaluations - 3. Greater than 2g/day of proteinuria - 4. No contraindications to treatment with corticosteroids or ACTH - 5. Women of childbearing potential will agree to use effective forms of birth control throughout this study